ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CELC
VCYT (73) ACHC (38) CDNA (71) CLOV (36) ⌘ Pro Terminal →

Celcuity Inc. (CELC) — RQD Stock Rating Cockpit

$67.07 -2.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $66.58

Celcuity Inc. (CELC) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.38B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CELC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CELC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Celcuity Inc. (NASDAQ: CELC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $67.07 (-2.98% 1D, market cap $3.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELC ranks #748 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CELC compare to VCYT and ACHC in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), CELC carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCYT (Veracyte Inc.) holds a B grade (73/100 RQD, P/E 63.2x, ROIC 4.6%, cap $4.02B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -24.8%, cap $2.79B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CELC?
▼

Per CELC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001603454), Celcuity Inc. generated $482.1M in revenue (+52.0% YoY), -$177.0M in net income, and -$153.5M in free cash flow against $466.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $66.58 (-0.73%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (6)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$159 Bull$59 Base$46 Bear
📬 FREE CELC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELC)Realized 20D OHLCV Swing Band: ±12.2%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY CELC SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$63.19-5% Next Q
Q2 (-2Q)
26
Grade E$60.00+13.4% Next Q
Q3 (-1Q)
28
Grade E$68.07-1.5% Next Q
Current
31
Grade E$67.07-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CELC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CELC currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($76.75) and Max Pain ($70.42) forces dealer call-delta covering toward $158.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CELC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
49.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE14% OF RANGE
L: $54$67.07H: $151
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CELC

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and -4.53% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (25)

9/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like CELC
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELC)

  • ✓Walkthrough of CELC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CELC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.74%▼ DESCENDING CHANNEL
2026-11-03O $69.30H $69.30L $67.07C $67.07VOL 700.1K
RES: $77.27SUP: $45.49SMA50: $76.75SMA200: $100.3
$157.8$129.6$101.3$73.04$44.77RES $77.27SUP $45.49$67.072026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELC Butterfly Map → + Track CELC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +52.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CELC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CELC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELC)

Health Care Rank #748 of 1015 ⚔️ VCYT vs CELC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELC vs. VCYT, ACHC, CDNA, CLOV)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Celcuity Inc. (CELC) ranks #748 by composite RQD confidence (31/100, grade E) and #195 by equity capitalization ($3.38B). Within this direct 5-issuer industry benchmark cohort, VCYT leads on earnings valuation at 63.2x trailing P/E, while VCYT leads on capital efficiency and profitability with 4.6% ROIC and 70.1% gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CELC at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CELC ACTIVE
Celcuity Inc.
E 31/100 — — -35.0% -2.98% $3.38B Benchmark Subject
VCYT
Veracyte Inc.
B 73/100 63.2x 70.1% 4.6% -2.02% $4.02B /vcyt-vs-celc →
ACHC
Acadia Healthcare Company Inc.
D- 38/100 — — -24.8% -1.13% $2.79B /achc-vs-celc →
CDNA
CareDx Inc.
B- 71/100 — — -8.2% -1.75% $4.59B /cdna-vs-celc →
CLOV
Clover Health Investments Corp. (Class A)
D- 36/100 — — -29.3% -3.36% $2.37B /clov-vs-celc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001603454 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celcuity Inc. (CELC) reported GAAP revenue of $482.1M (+52.0% vs. FY2024 revenue of $317.1M , and +160.0% cumulative change since FY2023) , GAAP net income of -$177.0M, operating cash flow of -$153.3M, and free cash flow of -$153.5M (-83.4% YoY). On the balance sheet, CELC closed FY2025 with $466.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $482.1M -$177.0M -$153.3M -$153.5M $466.6M —
FY2024 (FY) 2024-12-31 $317.1M -$111.8M -$83.5M -$83.7M $245.1M —
FY2023 (FY) 2023-12-31 $185.4M -$63.8M -$53.8M -$53.8M — —

3. CELC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Celcuity Inc. (NASDAQ: CELC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $67.07 (-2.98% 1D, market cap $3.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELC ranks #748 in composite RQD confidence.

How does CELC compare to VCYT and ACHC in the Health Care sector?

Within the Health Care sector (Medical Specialities), CELC carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCYT (Veracyte Inc.) holds a B grade (73/100 RQD, P/E 63.2x, ROIC 4.6%, cap $4.02B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -24.8%, cap $2.79B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELC?

Per CELC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001603454), Celcuity Inc. generated $482.1M in revenue (+52.0% YoY), -$177.0M in net income, and -$153.5M in free cash flow against $466.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELC trading relative to its 50-day, 200-day, and 52-week technical levels?

CELC last traded at $67.07 (-2.98% on volume of 775,859 shares), positioning the stock -12.61% below its 50-day simple moving average ($76.75) and -33.10% below its 200-day simple moving average ($100.26). Across its 52-week range of $53.54 to $151.02, CELC sits at the 13.9% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($58.89 to $75.25).

Direct Sub-Reports: CELC RQD Cockpit CELC 12M Forecast CELC Earnings & Move CELC Dividends & DRIP CELC Insiders & 13F CELC Whale Options CELC Profit Sankey CELC News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

CELC — Celcuity Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Celcuity Inc. (CELC) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $67.07 (-2.98% 1D, market capitalization $3.38B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -4.53%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Celcuity Inc. (CELC) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry,. The reported revenue in every listed period is —, . — for the specific product or customer base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Celcuity Inc. (CELC) reported $482.1M in annual revenue (up from $317.1M in FY2024, +52.0% YoY) and -$177.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($185.4M revenue, -$63.8M net income) through FY2025, CELC scaled operating cash flow to -$153.3M and free cash flow to -$153.5M, backed by $466.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.53% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $53.54 – $151.02 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), CELC carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can CELC sustain or expand its — operating margin and -35.0% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $482.1M and free cash flow of -$153.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CELC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CELC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Celcuity Inc. (CELC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CELC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CELC Bull vs. Bear Conversation Board — What's Your Call at $67.07?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CELC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CELC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $82.26 (+19.0%)
📌 Pinned Debate

Cash balance rose to $165.7M in FY 2025 from $22.5M in FY 2024, giving the company a larger liquidity base to fund operations.

Don't sleep on CELC's setup in Health Care. Cash balance rose to $165.7M in FY 2025 from $22.5M in FY 2024, giving the company a larger liquidity base to fund operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $53.92 (-22.0%)
Spot @ $69.13

Operating losses widened to -$172.2M in FY 2025 with zero reported revenue and negative FCF of -$153.5M, and the RQD score is 32 (E).

I respect the product at Celcuity Inc., but the stock at $69.13 is a different story. Operating losses widened to -$172.2M in FY 2025 with zero reported revenue and negative FCF of -$153.5M, and the RQD score is 32 (E).. FCF yield is -4.53% and RQD sits at 31/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%